Fundeni Clinical Institute
- Address
- Soseaua Fundeni 258, 022328 Bucharest, Romania
Oncology – Colorectal Cancer Research
The Fundeni Clinical Institute is advancing treatment options for patients with Microsatellite Instability‑High (MSI‑H) or Mismatch Repair Deficient (dMMR) stage IV colorectal cancer, focusing on innovative immunotherapy strategies.
- Combination immunotherapy regimens targeting tumor biomarkers
- Assessment of objective response using standardized imaging criteria
- Evaluation of safety and tolerability in metastatic disease
- Exploration of biomarkers to personalize therapy selection
The goal is to improve response rates and extend survival for individuals with advanced colorectal cancer by testing new therapeutic agents alongside established checkpoint inhibitors.
Cardiovascular Disease Primary Prevention
Researchers at the institute are conducting a study to determine whether the novel RNA‑based drug inclisiran can lower the incidence of major adverse cardiovascular events in high‑risk patients targeted for atherosclerotic cardiovascular disease (ASCVD) prevention.
- Investigation of long‑term lipid‑lowering effects
- Measurement of cardiovascular outcomes such as heart attack, stroke, and urgent revascularization
- Placebo‑controlled design to establish efficacy
- Focus on individuals with elevated risk factors for heart disease
This research aims to demonstrate that reducing cholesterol through inclisiran can significantly decrease the risk of heart‑related events, offering a new preventive option for patients at risk of cardiovascular disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 16 therapeutic areas and 15 of 219 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 202 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 40 by active trials.
- 1Celgene Corp.4active
lock +39 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG9trials
lock +21 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Fundeni Clinical Institute
lock Showing 1 of 120 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 219 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorouracil | 10 | Unknown | 2019-08-26 | 2026-03-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.